Three novel HIV products from Gilead and Tibotec will earn combined peak year sales of over $5 billion

Gilead and Tibotec (a wholly-owned subsidiary of Johnson & Johnson) remain on track to launch three novel HIV/AIDS treatment options in the next two years - Gilead's Quad (a four drug, one pill, once-daily regimen), Tibotec's rilpivirine and Gilead/Tibotec's rilpivirine/emtricitabine/tenofovir fixed-dose combination product. Together, these products have the potential for combined peak-year sales in excess of $5 billion in the USA, France, Germany, Italy, Spain, the UK and Japan.

According to a Decision Resources Pharmacor 2010 report Human Immunodeficiency Virus, through 2018, Gilead's Quad will earn peak-year sales of up to $2.5 billion and Gilead/Tibotec's rilpivirine/emtricitabine/tenofovir will earn peak-year sales of up to $3 billion. Robust uptake of these agents will be driven by their favorable safety and efficacy profiles and convenient dosing which make them ideal products for treatment-naive patients - the most lucrative segment of the HIV market.